Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies

Clinical Gastroenterology and Hepatology · In press · Journal article · DOI 10.1016/j.cgh.2026.02.018 · Cited by 5 (Crossref)

Free full text

Authors (20)

Remo Panaccione, Julián Panés, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel, James O. Lindsay, Filip Baert, Raja Atreya, Séverine Vermeire, Toshimitsu Fujii, Elena Dubcenco, Justin Klaff, Benjamin Duncan, Smitha Suravaram, Irina Fish, Ana P. Lacerda, Ramona Vladea, Sharanya Ford, Saajan Shah, Samuel I. Anyanwu, David T Rubin

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume
24
Issue
10
Pages
2783-2795
Year
2026

Citation

Panaccione, R., Panés, J., Peyrin-Biroulet, L., et al. (2026). Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.02.018

Related articles

Metrics

Citations (Crossref)
5